Dawn B. Davis, MD Print Friendly Page
Faculty, University of Wisconsin School of Medicine and Public HealthDr. Davis devotes the majority of her time to basic and translational research on diabetes and obesity and maintains an active clinical practice encompassing all aspects of endocrinology, with specific interests in both type 1 and type 2 diabetes, rarer forms of diabetes including genetic and acquired, endocrine complications after gastric bypass surgery, obesity and hypoglycemia.
Specialties
Endocrinology, Diabetes and Metabolism
UW Health Clinics
Hospital Affiliation(s)
University of Wisconsin Hospital and Clinics (primary)
Meriter Hospital, Veterans Hospital - Wm. S. Middleton Memorial (secondary)
Languages Spoken
| English |
| Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000. |
UW School of Medicine and Public Health
| Department of Medicine |
Professional Certifications and Education
| Board Certification |
Internal Medicine
Endocrinology, Diabetes & Metabolism |
| Fellowship |
University of Wisconsin Hospital and Clinics, Madison, WI
|
| Residency |
University of Washington School of Medicine, Seattle
|
| Medical School |
University of Chicago, Pritzker School of Medicine, Chicago, IL, 2003
|
Programs & Conditions
PubMed Articles
-
Dhital SM Shenker Y Meredith M Davis DB .
A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients. Endocr Pract. 2012 Sep-Oct;18(5):712-9
[PubMed ID: 22784834]
-
Davis DB Lavine JA Suhonen JI Krautkramer KA Rabaglia ME Sperger JM Fernandez LA Yandell BS Keller MP Wang IM Schadt EE Attie AD .
FoxM1 is up-regulated by obesity and stimulates beta-cell proliferation. Mol Endocrinol. 2010 Sep;24(9):1822-34
[PubMed ID: 20660304]
-
Lavine JA Raess PW Stapleton DS Rabaglia ME Suhonen JI Schueler KL Koltes JE Dawson JA Yandell BS Samuelson LC Beinfeld MC Davis DB Hellerstein MK Keller MP Attie AD .
Cholecystokinin is up-regulated in obese mouse islets and expands beta-cell mass by increasing beta-cell survival. Endocrinology. 2010 Aug;151(8):3577-88
[PubMed ID: 20534724]
-
Lavine JA Raess PW Davis DB Rabaglia ME Presley BK Keller MP Beinfeld MC Kopin AS Newgard CB Attie AD .
Contamination with E1A-positive wild-type adenovirus accounts for species-specific stimulation of islet cell proliferation by CCK: a cautionary note. Mol Endocrinol. 2010 Feb;24(2):464-7
[PubMed ID: 20081104]
-
Lavine JA Raess PW Davis DB Rabaglia ME Presley BK Keller MP Beinfeld MC Kopin AS Newgard CB Attie AD .
Overexpression of pre-pro-cholecystokinin stimulates beta-cell proliferation in mouse and human islets with retention of islet function. Mol Endocrinol. 2008 Dec;22(12):2716-28
[PubMed ID: 18845673]
-
Chen J Hui ST Couto FM Mungrue IN Davis DB Attie AD Lusis AJ Davis RA Shalev A .
Thioredoxin-interacting protein deficiency induces Akt/Bcl-xL signaling and pancreatic beta-cell mass and protects against diabetes. FASEB J. 2008 Oct;22(10):3581-94
[PubMed ID: 18552236]
-
Keller MP Choi Y Wang P Davis DB Rabaglia ME Oler AT Stapleton DS Argmann C Schueler KL Edwards S Steinberg HA Chaibub Neto E Kleinhanz R Turner S Hellerstein MK Schadt EE Yandell BS Kendziorski C Attie AD .
A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibility. Genome Res. 2008 May;18(5):706-16
[PubMed ID: 18347327]
